Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854183 | 0.94 | SIGMAR1 (0.58) | NAAASIGMAR1TMEM97HDAC3NPC1 | |
| SCHEMBL1853512 | 0.91 | NAAA (0.64) | NAAASIGMAR1TMEM97HDAC3NPC1 | |
| SCHEMBL1859658 | 0.91 | NAAA (0.64) | NAAASIGMAR1TMEM97HDAC3NPC1 | |
| SCHEMBL1851125 | 0.91 | NAAA (0.64) | NAAASIGMAR1TMEM97HDAC3NPC1 | |
| SCHEMBL1854062 | 0.91 | NAAA (0.51) | NAAASIGMAR1TMEM97STAT3 | |
| SCHEMBL1854504 | 0.91 | SIGMAR1 (0.49) | NAAASIGMAR1TMEM97NPC1RAB9A | |
| SCHEMBL1853750 | 0.89 | NPC1 (0.62) | NAAASIGMAR1TMEM97HDAC3NPC1 | |
| SCHEMBL1854634 | 0.89 | STAT3 (0.44) | NAAASIGMAR1TMEM97HDAC3NPC1 | |
| SCHEMBL1239475 | 0.89 | NAAA (0.53) | NAAASIGMAR1TMEM97HDAC3NPC1 | |
| SCHEMBL5044268 | 0.88 | NAAA (0.60) | NAAASIGMAR1TMEM97HDAC3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | claimed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | claimed |
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | claimed |
| EP-1732534-A1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2006-12-20 | — | — | EP | claimed |
| WO-2005082347-A1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | APLLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-09-09 | — | — | WO | claimed |
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | TNNI3, TNNT2, ADM2 | NAAA 684/4885SIGMAR1 2165/4885TMEM97 2395/4885 |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | NAAA 1643/4885SIGMAR1 4339/4885TMEM97 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.